Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 10/20 | 0.40 |
| ▸ | GRM6 | O15303 | 8/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.40 |
| ▸ | GRM5 | P41594 | 5/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 5/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GRM8 | O00222 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3733593 | 1.00 | SLC6A4 (0.41) | SLC6A4GRM2GRM6GRM4GRM5 | |
| SCHEMBL26746340 | 1.00 | SLC6A4 (0.41) | SLC6A4GRM2GRM6GRM4GRM5 | |
| Water SCHEMBL10753838 | 0.98 | SLC6A4 (0.40) | SLC6A4GRM2GRM6GRM4GRM5 | |
| Water SCHEMBL10753833 | 0.98 | SLC6A4 (0.40) | SLC6A4GRM2GRM6GRM4GRM5 | |
| SCHEMBL22582250 | 0.87 | GRM2 (0.47) | SLC6A4GRM2GRM6GRM4GRM5 | |
| SCHEMBL8663610 | 0.85 | THRB (0.48) | SLC6A4GRM2GRM6GRM4GRM5 | |
| SCHEMBL2009762 | 0.83 | THRB (0.35) | THRBCYP2C9HSD11B1 | |
| SCHEMBL9457723 | 0.83 | THRB (0.35) | THRBCYP2C9HSD11B1 | |
| SCHEMBL7976925 | 0.82 | GRM2 (0.43) | SLC6A4GRM2GRM6GRM4GRM5 | |
| SCHEMBL26747648 | 0.82 | SLC1A2 (0.37) | THRBCYP2C9HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| WO-2023286823-A1 | PHARMACEUTICAL COMPOSITION | 国立大学法人大阪大学 | 2023-01-19 | — | — | WO | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| WO-2022122668-A1 | COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-06-16 | — | — | WO | claimed |
| EP-4008330-A1 | COMBINED INHIBITION OF AMINO ACID TRANSPORTERS FOR INHIBITING HUMAN PLASMACYTOID DENDRITIC CELL ACTIVITY DURING AUTOIMMUNITY | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-06-08 | — | — | EP | claimed |
| EP-3760197-B1 | TRANSPORT PROTEIN INHIBITOR FOR REDUCING EXPRESSION OF PD-1 | INST BASIC MEDICAL SCIENCES CAMS (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC MEDTECH CORP (US) | 2021-09-16 | — | — | US | claimed |
| EP-3490543-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC-Medtech Corp. (US) | 2019-06-05 | — | — | EP | claimed |
| US-20060094785-A1 | Use of amino acids for treatment of various conditions | ROCHESTER, UNIVERSITY OF | 2006-05-04 | — | — | US | claimed |
| US-6984482-B2 | Top-coating composition for photoresist and process for forming fine pattern using the same | HYNIX SEMICONDUCTOR INC. (KR) | 2006-01-10 | — | — | US | claimed |
| EP-1575501-A2 | USE OF AMINO ACIDS FOR TREATMENT OF VARIOUS CONDITIONS | University of Rochester (US) | 2005-09-21 | — | — | EP | claimed |
| US-20040033252-A1 | Agents for recoverying from or preventing fatigue in the central nerve system and foods for recovering from or preventing fatigue | NEWSHOLME, ERIC A. (GB) | 2004-02-19 | — | — | US | claimed |
| WO-2004006841-A2 | USE OF AMINO ACIDS FOR TREATMENT OF VARIOUS CONDITIONS | UNIVERSITY OF ROCHESTER (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030108815-A1 | Top-coating composition for photoresist and process for forming fine pattern using the same | HYNIX SEMICONDUCTOR INC. (KR) | 2003-06-12 | — | — | US | claimed |
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | claimed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-5284774-A | Antineoplastic, system-L specific amino acid nitrogen mustards | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECY. OF THE DEPT. OF HEALTH & HUMAN RESOURCES (US) | 1994-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | SLC5A1, SLC5A2, SLC5A6 | SLC6A4 103/4885GRM2 3630/4885GRM6 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.